| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Anne McGeorge is Director at TOIIW, with reported holdings spanning 3 companies. Anne McGeorge's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider.
Anne McGeorge has 16 Form 4 filings on record from June 2019 to August 2026, across 3 companies: Director at Dianthus Therapeutics (DNTH), 2019–2026; Director at The Oncology Institute (TOIIW), 2026; Director at Oncology Institute (TOI), 2022–2025.
The 24 reported transactions were 9 stock awards, 8 option or other derivative awards, 5 open-market sales and 2 option exercises.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $845K.
The only open-market sale was 7,750 shares of DNTH at an average $109.01 on August 10, 2026, about $845K.